22.10.2021 19:24

Aflac (AFL) to Report Q3 Earnings: Is a Beat in the Cards?

Folgen
Werbung
Aflac Incorporated AFL is scheduled to release third-quarter 2021 results on Oct 27, after the market closes.Q3 EstimatesThe Zacks Consensus Estimate for the company’s earnings per share is pegged at $1.30, indicating a fall of 6.47% from the prior-year quarter’s reported figure. The consensus mark for revenues stands at $5.38 billion, which suggests a decline of 4.97% from the year-ago quarter’s reported number.Factors to Impact Q3 ResultsAt Aflac’s Japan segment, revenues are likely to have gained from increased premium, driven by higher sales of its new medical product and improved pandemic conditions compared with the prior-year scenario.At the U.S. segment, sales are likely to have gone up, aided by improved pandemic conditions.Net investment income is likely to have gone up, primarily on higher variable net investment income.Expenses are likely to have been high, weighing down the margins. Constant digital investments in its core technological platforms and their upgrades might have flared up costs. However, the company is trying to control costs wherever possible and to this end, it took numerous cost-curbing measures, which might have partially offset the stress on margins.Earnings Surprise HistoryThe company boasts an impressive earnings surprise history as its bottom line beat estimates in each of the trailing four quarters, the average being 19.92%. This is depicted in the chart below:What Our Quantitative Model PredictsThe proven Zacks model predicts an earnings beat for Aflac this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.Earnings ESP:  Aflac has an Earnings ESP of +1.44%. This is because the Most Accurate Estimate of $1.32 is pegged higher than the Zacks Consensus Estimate of $1.30. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank:  Aflac has a Zacks Rank #2, currently.Other Stocks to ConsiderHere are some other stocks worth considering from the insurance space with the perfect mix of elements to surpass estimates in their upcoming releases.Cigna Corp. CI currently has an Earnings ESP of +2.19% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here..Athene Holding Ltd. ATH currently has an Earnings ESP of +1.71% and is a Zacks #2 Ranked stock.MetLife, Inc. MET currently has an Earnings ESP of +1.21% and is a Zacks #3 Ranked stock. Zacks Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MetLife, Inc. (MET): Free Stock Analysis Report Aflac Incorporated (AFL): Free Stock Analysis Report Cigna Corporation (CI): Free Stock Analysis Report Athene Holding Ltd. (ATH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Quelle: Zacks

Nachrichten zu Aflac Inc

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Aflac Inc

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
21.03.2018Aflac Equal WeightBarclays Capital
03.07.2017Aflac Equal WeightBarclays Capital
01.05.2017Aflac UnderperformRBC Capital Markets
02.02.2017Aflac UnderperformRBC Capital Markets
09.12.2016Aflac UnderperformRBC Capital Markets
16.05.2012Aflac outperformRBC Capital Markets
14.05.2012Aflac overweightBarclays Capital
27.04.2012Aflac sector outperformScotia Capital Markets
26.04.2012Aflac outperformRBC Capital Markets
27.03.2012Aflac overweightBarclays Capital
21.03.2018Aflac Equal WeightBarclays Capital
03.07.2017Aflac Equal WeightBarclays Capital
10.05.2016Aflac Mkt PerformFBR Capital
27.04.2016Aflac NeutralUBS AG
27.04.2016Aflac Sector PerformRBC Capital Markets
01.05.2017Aflac UnderperformRBC Capital Markets
02.02.2017Aflac UnderperformRBC Capital Markets
09.12.2016Aflac UnderperformRBC Capital Markets
09.01.2012Aflac sellUBS AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Aflac Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Neue Virussorgen: DAX geht tiefrot ins Wochenende -- Ausverkauf in den USA -- Lufthansa fliegt vorerst weiter nach Südafrika -- Tesla verzichtet auf staatliche Förderung -- Software AG, K+S im Fokus

Apple macht iPhone in der Türkei über Nacht mehr als 25 Prozent teurer. Ocugen-Aktie: FDA stoppt Covaxin-Impfstoff. BioNTech prüft Wirksamkeit seines Impfstoffs gegen neue Corona-Variante. Nextcloud legt Beschwerde gegen Microsoft beim Bundeskartellamt ein. Kryptowährungen geben wegen neuer Virusvariante kräftig nach. Deutsche Bank: Entscheidend ob Impfstoffe gegen Variante wirken.

Umfrage

Sind Sie in Kryptowährungen wie Bitcoin, Ether & Co. investiert?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln